Glimulin-2 MF Tablet PR is a fixed-dose combination medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The combination of these two agents provides complementary mechanisms of action, offering improved efficacy in lowering blood glucose compared to monotherapy. Glimulin-2 MF Tablet PR is typically prescribed when diet, exercise, and monotherapy have not achieved adequate glycemic control. It is important to initiate therapy with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis, a rare but serious adverse effect associated with Metformin. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to Glimepiride. Regular monitoring of blood glucose levels, renal function, and adherence to lifestyle modifications is essential to optimize therapeutic outcomes. This medication should be used under medical supervision with appropriate patient education on recognizing hypoglycemia symptoms.